Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review

S Troisi, V Giudice, M Troisi, D Morini, A Crudele… - Acta …, 2023 - karger.com
Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of
newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available …
相关文章

Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review

S Troisi, V Giudice, M Troisi, D Morini… - Acta …, 2023 - pubmed.ncbi.nlm.nih.gov
Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of
newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available …

Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review

S Troisi, V Giudice, M Troisi, D Morini… - ACTA …, 2023 - iris.unisa.it
Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of
newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available …

Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review

S Troisi, V Giudice, M Troisi, D Morini, A Crudele… - Acta …, 2023 - karger.com
Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of
newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available …

Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review.

S Troisi, V Giudice, M Troisi, D Morini… - Acta …, 2023 - europepmc.org
Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of
newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available …